19 Results for "

non-human primate model

" in MedChemExpress (MCE) Product Catalog:
Products (19)

19 Results for "non-human primate model" in MCE Product Catalog:

7
7 Publications Verification
Cat. No.: HY-P1717
CAS No.: 1427001-89-5
Synonyms: Cp40
Research Areas:  

Inflammation/Immunology

AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .
loading...
    loading...
7
7 Publications Verification
Cat. No.: HY-P1717B
Synonyms: Cp40 acetate
Research Areas:  

Inflammation/Immunology

AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .
loading...
    loading...
7
7 Publications Verification
Cat. No.: HY-P1717A
CAS No.: 1789738-04-0
Synonyms: Cp40 TFA
Research Areas:  

Inflammation/Immunology

AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P99037
CAS No.: 2211985-36-1
Synonyms: M281

Target:  

Fc Receptor (FcR)

Research Areas:  

Inflammation/Immunology

Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99302
CAS No.: 2235419-62-0
Synonyms: BMS-931699 Antibody

Target:  

CD28

Research Areas:  

Inflammation/Immunology

Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is an anti-CD28 domain antibody antagonist. Lulizumab inhibits T-cell activation by selectively targeting the CD28 signal. In a sensitized non-human primate kidney transplantation model, when combined with Carfilzomib (HY-10455), Lulizumab can regulate immune cells and prolong the survival time of the graft .
loading...
    loading...
Cat. No.: HY-171821
Synonyms: SGN-PDL1V
PF-08046054 (SGN-PDL1V) is a PD-L1-directed Antibody-drug conjugate (ADC), which is comprised of an anti-PD-L1 antibody conjugated to VcMMAE (HY-15575). PF-08046054 is direct cytotoxicity to PD-L1-expressing tumor cells via the intracellular delivery of MMAE. PF-08046054 can be used for the study of solid tumors
loading...
    loading...
Cat. No.: HY-153484A
CAS No.: 849758-52-7
Research Areas:  

Neurological Disease

Bevasiranib sodium is a siRNA that targets and silences VEGF-A. Bevasiranib sodium activates the RNA-induced silencing complex to degrade VEGF-A mRNA, mediates TLR3-related inhibition of choroidal neovascularization, and triggers RNA interference-mediated gene silencing through endogenous eukaryotic RNAi mechanisms. After intravitreal injection, Bevasiranib sodium distributes to various ocular tissues and resists degradation by intraocular nucleases, reducing choroidal neovascularization area and alleviating vascular leakage. Bevasiranib sodium can be used in research related to macular degeneration .
loading...
    loading...
Cat. No.: HY-123669
CAS No.: 204204-73-9
Research Areas:  

Cardiovascular Disease

R-138727, the major active metabolite of Prasugrel (HY-15284), is a highly potent and selective irreversible antagonist of the P2Y12 receptor, with an IC50 of 2.5 μM. R-138727 covalently binds to the P2Y12 receptor on the platelet surface, blocking adenosine diphosphate-mediated platelet activation and aggregation. R-138727 can be used to study stroke, cerebral infarction and neurological deficits.
loading...
    loading...
Cat. No.: HY-P991467

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

RG-7258 is a human monoclonal antibody (mAb) targeting CRLF2. RG-7258 blocks dendritic cell activation and mast cell cytokine release. RG-7258 reduces Th2 inflammation in a non-human primate model of allergic lung inflammation. RG-7258 can be used in asthma research .
loading...
    loading...
Cat. No.: HY-153484
CAS No.: 959961-96-7
Research Areas:  

Neurological Disease

Bevasiranib is a siRNA that targets and silences VEGF-A. Bevasiranib activates the RNA-induced silencing complex to degrade VEGF-A mRNA, mediates TLR3-related inhibition of choroidal neovascularization, and triggers RNA interference-mediated gene silencing through endogenous eukaryotic RNAi mechanisms. After intravitreal injection, Bevasiranib distributes to various ocular tissues and resists degradation by intraocular nucleases, reducing choroidal neovascularization area and alleviating vascular leakage. Bevasiranib can be used in research related to macular degeneration .
loading...
    loading...
Cat. No.: HY-P992369

Target:  

VISTA

Research Areas:  

Cancer

HMBD-002 is an Fc-independent, non-depleting IgG4 subclass antibody that targets VISTA and VSIG3. It is widely used in research related to various solid tumors, including colon cancer, triple-negative breast cancer, and non-small cell lung cancer. HMBD-002 blocks the interactions of VISTA with VSIG3 and LRIG1, relieves immunosuppression without depleting VISTA-positive cells, activates the cytotoxic program of CD8 + T cells, and drives the type I interferon signaling pathway. HMBD-002 reprograms tumor-associated macrophages to the M1 phenotype, reduces tumor infiltration of inhibitory myeloid cells, thereby significantly inhibiting tumor growth and improving survival. HMBD-002 is well tolerated in rodent and non-human primate animal models .
loading...
    loading...
Cat. No.: HY-176522
Research Areas:  

Cancer

Oligomer-lipid 7C1 is an ionazable lipid. Oligomer-lipid 7C1 can be generated through the reaction of low-molecular-weight polyamine with lipid. Oligomer-lipid 7C1 efficiently binds siRNA to form nanoparticle. Oligomer-lipid 7C1 can induce RNA interference in endothelial cells of multiple organs in nonhuman primates. Oligomer-lipid 7C1 is able to deliver siRNA to endothelial cells and facilitates endothelial function modification in mouse models of vascular permeability, emphysema, primary tumor growth and metastasis .
loading...
    loading...
Cat. No.: HY-185743
ZW-191 is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα). ZW-191 consists of ZW-191 Antibody (HY-P992515) as the antibody component and MC-GGFG-AM-(10Me-11F-Camptothecin) (HY-153360) as the linker-payload component. ZW-191 possesses excellent tumor sphere penetration, cellular internalization and payload delivery capabilities, and can release a topoisomerase 1 inhibitor inside tumor cells to inhibit tumor cell activity. ZW-191 exerts a potent bystander effect on both antigen-positive and antigen-negative cells. ZW-191 exhibits prominent activity in xenograft models of cell lines with different FRα expression levels. ZW-191 can be used in studies related to ovarian cancer, non-small cell lung cancer, endometrial cancer and triple-negative breast cancer .
loading...
    loading...
Cat. No.: HY-183951
CAS No.: 2962087-36-9
Research Areas:  

Neurological Disease Cancer

TNG456 is an orally active, CNS-penetrant, selective, MTA-cooperative PRMT5 inhibitor. TNG456 drives dose-dependent antitumor activity in mouse xenograft models. TNG456 can be used for the research of MTAP-null solid tumors, including gliomas, and CNS metastases .
loading...
    loading...
Cat. No.: HY-P992515

Research Areas:  

Cancer

ZW-191 Antibody is a humanized IgG1 antibody targeting folate receptor α (FRα). ZW-191 Antibody is conjugated with MC-GGFG-AM-(10Me-11F-Camptothecin) (HY-153360) to generate the antibody-drug conjugate (ADC) ZW-191 (HY-185743). ZW-191 Antibody-based ADC exerts a potent bystander effect on both antigen-positive and antigen-negative cells. ZW-191 Antibody is applicable to research related to ovarian cancer, non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer .
loading...
    loading...
Cat. No.: HY-183203
CAS No.: 1451993-12-6
Target:  

mAChR

Research Areas:  

Neurological Disease

VU0476406 is a blood-brain barrier-permeable and selective muscarinic acetylcholine receptor subtype 4 (M4) activator with human EC50 of 91.0 nM and human pEC50 of 7.04. VU0476406 potentiates endogenous acetylcholine activity at M4 receptors. VU0476406 can be used for the research of Parkinson's disease .
loading...
    loading...
Cat. No.: HY-P992352
ES005 is an anti-tumor compound and LAG3 inhibitor. ES005 blocks the interactions of LAG3 with MHC-II, LSECtin and FGL1, thereby effectively reversing the LAG3-mediated inhibition of T cell activation and NFAT reporter gene expression. ES005 exhibits significant tumor growth inhibitory effects in syngeneic mouse breast tumor models using humanized LAG3 knock-in mice. ES005 can be used for breast tumor-related research .
loading...
    loading...
Cat. No.: HY-P992026

Target:  

ADC Antibodies

Research Areas:  

Cancer

ADV-101 Antibody is a monoclonal antibody inhibitor targeting IL-1RAP. ADV-101 Antibody can be used to synthesize the antibody-drug conjugate (ADC) ADV-101. ADV-101 Antibody can be used to research related to cancer .
loading...
    loading...
Cat. No.: HY-122557
CAS No.: 1259929-13-9
Target:  

5-HT Receptor

Research Areas:  

Neurological Disease

AZD3676 is an orally active and blood-brain barrier-permeable ligand for 5-HT1 and 5-HT1 receptors, with nanomolar binding affinity. AZD3676 is applicable to research related to cognitive impairment in Alzheimer's disease .
loading...
    loading...
  • 1